Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has a beta value of -0.04 and has seen 1.93 million shares traded in the last trading session. The company, currently valued at $261.46M, closed the last trade at $3.25 per share which meant it lost -$0.12 on the day or -3.56% during that session. The KPTI stock price is -353.23% off its 52-week high price of $14.73 and 24.62% above the 52-week low of $2.45. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.46 million shares traded. The 3-month trading volume is 2.69 million shares.
The consensus among analysts is that Karyopharm Therapeutics Inc. (KPTI) is an Overweight stock at the moment, with a recommendation rating of 2.20. 0 analysts rate the stock as a Sell, while 2 rate it as Overweight. 4 out of 10 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.57.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) trade information
Sporting -3.56% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/23/23 when the KPTI stock price touched $3.25 or saw a rise of 5.25%. Year-to-date, Karyopharm Therapeutics Inc. shares have moved -4.41%, while the 5-day performance has seen it change -1.52%. Over the past 30 days, the shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have changed 7.62%. Short interest in the company has seen 13.69 million shares shorted with days to cover at 7.88.
Karyopharm Therapeutics Inc. (KPTI) estimates and forecasts
Figures show that Karyopharm Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -26.97% over the past 6 months, with this year growth rate of -16.97%, compared to 11.30% for the industry. Other than that, the company has, however, lowered its growth outlook for the 2023 fiscal year revenue. Growth estimates for the current quarter are 17.40% and -193.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be -25.10%.
8 analysts offering their estimates for the company have set an average revenue estimate of $34.56 million for the current quarter. 8 have an estimated revenue figure of $38.01 million for the next quarter concluding in Dec 2022. Year-ago sales stood $25.8 million and $126.27 million respectively for this quarter and the next, and analysts expect sales will grow by 34.00% for the current quarter and -69.90% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 10.80% over the past 5 years.
Karyopharm Therapeutics Inc. is expected to release its next earnings report between February 06 and February 10 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s Major holders
Insiders own 8.89% of the company shares, while shares held by institutions stand at 89.75% with a share float percentage of 98.51%. Investors are also buoyed by the number of investors in a company, with Karyopharm Therapeutics Inc. having a total of 219 institutions that hold shares in the company. The top two institutional holders are State Street Corporation with over 10.36 million shares worth more than $46.73 million. As of Jun 29, 2022, State Street Corporation held 12.98% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 8.12 million shares as of Jun 29, 2022. The firm’s total holdings are worth over $36.63 million and represent 10.18% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Sep 29, 2022, the former fund manager holds about 9.08% shares in the company for having 7.25 million shares of worth $39.56 million while later fund manager owns 2.01 million shares of worth $9.06 million as of Jun 29, 2022, which makes it owner of about 2.52% of company’s outstanding stock.